Meiji Yasuda Doubles 2026 Super-Long Government Bond Buying Plan
Original Report
Meiji Yasuda Life Insurance Co. aims to buy more than ¥2 trillion ($12 billion) of super-long Japanese government bonds in the fiscal year ending March 2027, doubling its earlier purchase plan on the...
Meiji Yasuda Life Insurance Co. aims to buy more than ¥2 trillion ($12 billion) of super-long Japanese government bonds in the fiscal year ending March 2027, doubling its earlier purchase plan on the view that yields have climbed to desirable levels.
Glass House Analysis
Treasury market movements signal how investors view America's fiscal health and economic trajectory. Rising yields mean the government pays more to borrow, which eventually shows up in taxes or reduced services. For average Americans, this translates to higher mortgage rates, more expensive business loans, and a general tightening of financial conditions that makes everything from buying a home to starting a business more challenging.
The implications extend beyond the immediate news cycle. Every economic development creates ripples that affect employment, prices, and opportunities in ways that may not be immediately visible but are deeply felt. By tracking these connections, we can better understand how the economy truly works—not as an abstract machine, but as a human system shaped by and shaping the lives of millions.
Enjoyed this analysis?
Get the Glass House Briefing every morning—market news that actually makes sense, delivered free to your inbox.
No spam. Unsubscribe anytime.
More Stories
Happy Birthday, America. Our Best Tradition Is Taking on the Powerful
A sunny view of egalitarian tendencies in the history of America.
Yen Sinks to Lowest Level Since 1986
The yen just hit its weakest level against the dollar in four decades. Japan has raised interest rates and spent billions defending its currency. Yet the yen keeps sliding. Mia Glass explains why....
French biotech stock soars 30% after new data on experimental medicine
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.
Segantii Trial Enters Endgame as Defense Wraps Up Testimony
The insider trading trial of Segantii Capital Management came to a halt on Tuesday, following more than a month of testimony that put a magnifying glass on a tiny series of trades that took place...